Another study using the PISE model of epilepsy found that activation of TRPV4 by the specific agonist GSK1016790A increased pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), while the inhibition of TRPV4 by HC-067047, a selective TRPV4 antagonist, significantly increased cell survival post status epilepticus (Wang et al., 2019). The gene discussed is TRPV4; the disease is epilepsy.